Niagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical ...

This initiative is part of the brand’s commitment to providing guests with science-backed health and wellness services.

Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine ...

Niagen Bioscience Inc. (NASDAQ:NAGE) saw its stock rise 2% after securing an exclusive global commercial license from Norway’s Haukeland University Hospital to develop its nicotinamide riboside ...

The buzzy supplement is beloved by celebrities and starting to show up in skin care. But what can it actually do?

Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Partnerships 310-405-5227 [email protected]. Niagen Bioscience Investor Relations Contact: ...

Niagen Bioscience (NASDAQ:NAGE) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.

Niagen Bioscience, Inc. and Subsidiaries Unaudited Condensed Consolidated Statements of Operations Three Months Ended March 31, 2025 2024 ...

Niagen Bioscience, Inc., the global authority on NAD+ with a focus on the science of healthy aging, today announces that senior management will participate at the Roth 15 th Annual London ...

LOS ANGELES (AP) — LOS ANGELES (AP) — Niagen Bioscience, Inc. (NAGE) on Wednesday reported net income of $5.1 million in its first quarter.

Niagen Bioscience management will host an investor conference call to discuss the first quarter 2025 financial results and provide a general business update on Wednesday, May 7, 2025, at 4:30 p.m ...